Soliris and You. Your Guide To Living With ahus. INDICATION & IMPORTANT SAFETY INFORMATION FOR SOLIRIS (eculizumab)
|
|
- Erik Willis
- 5 years ago
- Views:
Transcription
1 INDICATION & IMPORTANT SAFETY INFORMATION FOR SOLIRIS (eculizumab) INDICATION What is SOLIRIS? SOLIRIS is a prescription medicine called a monoclonal antibody. SOLIRIS is used to treat: adults and children with a disease called atypical Hemolytic Uremic Syndrome (ahus) SOLIRIS is not for use in treating people with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS) IMPORTANT SAFETY INFORMATION What is the most important information I should know about SOLIRIS? SOLIRIS is a medicine that affects your immune system. SOLIRIS can lower the ability of your immune system to fight infections. SOLIRIS increases your chance of getting serious and life-threatening meningococcal infections. Meningococcal infections may quickly become life-threatening and cause death if not recognized and treated early. 1. You must receive meningococcal vaccines at least 2 weeks before your first dose of SOLIRIS if you have not already had this vaccine. 2. If your doctor decided that urgent treatment with SOLIRIS is needed, you should receive meningococcal vaccination as soon as possible. 3. If you have not been vaccinated and SOLIRIS therapy must be initiated immediately, you should also receive 2 weeks of antibiotics with your vaccinations. 4. If you had a meningococcal vaccine in the past, you might need additional vaccination before starting SOLIRIS. Your doctor will decide if you need additional meningococcal vaccination. 5. Meningococcal vaccines reduce the risk of meningococcal infection but do not prevent all meningococcal infections. Call your doctor or get emergency medical care right away if you get any of these signs and symptoms of a meningococcal infection: headache with nausea or vomiting, headache and fever, headache with a stiff neck or stiff back, fever, fever and a rash, confusion, muscle aches with flu-like symptoms, eyes sensitive to light. Soliris and You Your Guide To Living With ahus Please see the accompanying full Prescribing Information and Medication Guide for SOLIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections. Alexion and Soliris are registered trademarks of Alexion Pharmaceuticals, Inc. 2018, Alexion Pharmaceuticals, Inc. All rights reserved. What is SOLIRIS? SOLIRIS is a prescription medicine called a monoclonal antibody. SOLIRIS is used to treat: adults and children with a disease called atypical Hemolytic Uremic Syndrome (ahus) SOLIRIS is not for use in treating people with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS)
2 INDICATION & IMPORTANT SAFETY INFORMATION FOR SOLIRIS (eculizumab) INDICATION What is SOLIRIS? SOLIRIS is a prescription medicine called a monoclonal antibody. SOLIRIS is used to treat: adults and children with a disease called atypical Hemolytic Uremic Syndrome (ahus) SOLIRIS is not for use in treating people with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS) Notes IMPORTANT SAFETY INFORMATION What is the most important information I should know about SOLIRIS? SOLIRIS is a medicine that affects your immune system. SOLIRIS can lower the ability of your immune system to fight infections. SOLIRIS increases your chance of getting serious and life-threatening meningococcal infections. Meningococcal infections may quickly become life-threatening and cause death if not recognized and treated early. 1. You must receive a meningococcal vaccine at least 2 weeks before your first dose of SOLIRIS if you have not already had this vaccine. 2. If your doctor decided that urgent treatment with SOLIRIS is needed, you should receive meningococcal vaccination as soon as possible. 3. If you have not been vaccinated and SOLIRIS therapy must be initiated immediately, you should also receive 2 weeks of antibiotics with your vaccinations. 4. If you had a meningococcal vaccine in the past, you might need additional vaccination before starting SOLIRIS. Your doctor will decide if you need additional meningococcal vaccination. 5. Meningococcal vaccines reduce the risk of meningococcal infection but do not prevent all meningococcal infections. Call your doctor or get emergency medical care right away if you get any of these signs and symptoms of a meningococcal infection: headache with nausea or vomiting, headache and fever, headache with a stiff neck or stiff back, fever, fever and a rash, confusion, muscle aches with flu-like symptoms, eyes sensitive to light. 2 Please see the accompanying full Prescribing Information and Medication Guide for SOLIRIS, including Boxed WARNING regarding Please see the accompanying full Prescribing Information and Medication Guide for SOLIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections. Please see Indication and Important Safety Information on pages serious and life-threatening meningococcal infections. Please see Indication and Important Safety Information on pages
3 Atypical Hemolytic Uremic Syndrome (ahus) is a rare and complicated disease, and you may have many questions about it. The information in this brochure can help you learn more about the disease, your life with ahus, and what to expect from treatment with Soliris (eculizumab). You can find the definitions of the underlined words in the Glossary on page 24. QUESTIONS ANSWERED IN THIS BROCHURE: What is ahus? p. 4 What is Soliris? p. 7 What do I need to know before taking Soliris? p. 8 How should I take Soliris? p. 10 What happens if I stop taking Soliris? p. 12 What is the Soliris REMS program? p. 14 Indication and Important Safety Information about Soliris p. 16 Where can I find out more? p. 22 Take an active role in your treatment and work with your doctor to help manage ahus. 3
4 What is ahus? ahus is a genetic disease. ahus is a disease caused by a genetic mutation in your DNA that affects the complement system. 1,2 This disease can develop at any age and is lifelong. The complement system is part of your immune system and is always on at a low level. 3,4 Common occurrences such as infections, allergies, or pregnancy can increase complement activity. 2,5 10 4
5 In people without ahus, the complement system functions as intended. Complement activity is increased only when needed and then returns to normal levels. 1,3,6 In people with ahus, changes in certain genes result in a loss of the body s ability to control complement activity. 1,3 Uncontrolled complement activity can result in damage to blood vessels and cause platelets to become overactive. 5,11,12 Overactive platelets can lead to thrombotic microangiopathy (TMA), a condition in which blood clots that block blood flow form within the small blood vessels of the body and cause vital organs to either suddenly fail or lose their ability to function over time. 6,11,12 When I was diagnosed with ahus in the hospital, I had no idea what that meant. I soon learned that this disease is rare and very serious. Patient with ahus Please see the accompanying full Prescribing Information and Medication Guide Please see accompanying full Prescribing for Information SOLIRIS, including and Medication Boxed WARNING Guide regarding for Soliris, serious including and life-threatening Boxed Warning 5 regarding serious meningococcal infection. meningococcal Please see infections. Important Please Safety see Information Indication and on pages Important Safety Information on pages
6 In ahus, the risk of TMA complications is lifelong. ahus is a chronic disease that can damage organs, such as the kidneys, and may lead to renal failure. 1 Work with your doctor to manage the complications of ahus. 6
7 What is Soliris? Soliris (eculizumab) is the first and only drug approved by the FDA to treat patients with ahus. Soliris inhibits uncontrolled complement activity in patients with ahus. 13 The safety and efficacy of Soliris in treating patients with ahus was studied in four clinical trials Many patients taking Soliris had an increase in their platelet counts, indicating that the small clots that had been trapping the platelets are no longer forming Many patients were able to discontinue prolonged plasma exchange or plasma infusion (PE/PI) Soliris reduced, and sometimes eliminated, the need for dialysis treatment in some patients with impaired kidney function The most common side effects in people with ahus treated with Soliris include: headache, diarrhea, high blood pressure (hypertension), common cold (upper respiratory infection), stomach-area (abdominal pain), vomiting, pain or swelling of your nose or throat (nasopharyngitis), low red blood cell count (anemia), cough, swelling of legs or feet (peripheral edema), nausea, urinary tract infections, fever. Tell your doctor about any side effect that bothers you or that does not go away. These are not all the possible side effects of Soliris. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at FDA Please see the accompanying full Prescribing Information and Medication Guide for SOLIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections. Please see Indication and Important Safety Information on pages
8 What do I need to know before taking Soliris? Before receiving your first Soliris (eculizumab) treatment Soliris can lower your immune system s ability to fight infections. Soliris increases your chance of getting serious and life-threatening meningococcal infections. This infection may quickly become life-threatening and can cause death if not recognized and treated early. 18 To help reduce the risk of such infections, you will need meningococcal vaccine(s) before beginning treatment with Soliris. You must receive meningococcal vaccines at least 2 weeks before your first dose of Soliris if you have not already had this vaccine If your doctor decided that urgent treatment with Soliris is needed, you should receive meningococcal vaccination as soon as possible»» In clinical studies, 75/100 patients with ahus were treated with Soliris less than 2 weeks after meningococcal vaccination»» 64 of these 75 patients received antibiotics to prevent meningococcal infection until at least 2 weeks after meningococcal vaccine If you have not been vaccinated and Soliris therapy must be initiated immediately, you should also receive 2 weeks of antibiotics with your vaccinations If you had a meningococcal vaccine in the past, you might need additional vaccination before starting Soliris Your doctor will decide if you need additional meningococcal vaccination Meningococcal vaccines reduce the risk of meningococcal infection but do not prevent all meningococcal infections. 18,19 Soliris may also increase the risk of other types of serious infections. If your child is treated with Soliris, make sure that your child receives vaccinations against Streptococcus pneumoniae and Haemophilus influenzae type b (Hib). Certain people may be at risk of serious infections with gonorrhea. Talk to your doctor about whether you are at risk for gonorrhea infection, about gonorrhea prevention, and regular testing. Certain fungal infections (aspergillus) may also happen if you take Soliris and have a weak immune system or a low white blood cell count. 8 Please see the accompanying full Prescribing Information and Medication Guide for SOLIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections. Please see Indication and Important Safety Information on pages
9 Soliris (eculizumab) increases your risk of acquiring serious and life-threatening meningococcal infections. Call your doctor or get emergency medical care right away if you get ANY of these signs and symptoms of a meningococcal infection 18 : headache with nausea or vomiting, headache and fever, headache with a stiff neck or stiff back, fever, fever and a rash, confusion, muscle aches with flu-like symptoms, eyes sensitive to light. Get IMMEDIATE medical attention if you experience any signs or symptoms of a meningococcal infection. 79
10 How should I take Soliris? Your doctor will discuss with you the appropriate dosing schedule for Soliris (eculizumab). Soliris should be administered at the FDA-recommended dosing schedule or within 2 days of the recommended schedule. 18 If you have an allergic reaction during your Soliris infusion, your doctor may decide to give you Soliris more slowly or to stop your infusion. After each infusion, you should be monitored for 1 hour for allergic reactions. 18 Serious allergic reactions. Serious allergic reactions can happen during your Soliris infusion. Tell your doctor or nurse right away if you get any of these symptoms during your Soliris infusion: Chest pain Trouble breathing or shortness of breath Swelling of your face, tongue, or throat Feel faint or pass out If you have an allergic reaction to Soliris, your doctor may need to infuse Soliris more slowly, or stop Soliris. See How will I receive Soliris? in the Medication Guide. 10
11 Dosing Considerations 18 Soliris is given through a vein as an intravenous (IV) infusion, usually over 35 minutes in adults and 1-4 hours in pediatric patients. If you are over 18 years of age, you will usually receive an infusion: Every week for 5 weeks Every 2 weeks thereafter If you are under 18 years of age, your doctor will decide the dose and frequency of treatment based on your age and weight. If you are also receiving PE/PI, additional doses of Soliris are required based on the Prescribing Information. If you miss a Soliris infusion, call your doctor right away. Our daughter was diagnosed with ahus and has been on Soliris therapy for almost two years. Her blood counts and her kidney function tests have improved. Parent of a patient taking Soliris Please see the accompanying full Prescribing Information and Medication Guide for SOLIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections. Please see Indication and Important Safety Information on pages
12 What happens if I stop taking Soliris? It is important that you follow the dosing schedule. You may be at risk for TMA complications if you 18 : Stop treatment Wait more than 2 weeks between doses Receive a lower dose In ahus clinical trials : 5 out of 18 patients who discontinued Soliris (eculizumab) developed TMA complications. 4 of the 5 patients were reinitiated with Soliris. Soliris continued to be effective in patients who stayed on treatment through 2 years. Your doctor may discontinue Soliris if you are undergoing treatment for a serious meningococcal infection or due to a side effect
13 Patients who stop using Soliris (eculizumab) are at risk for the return of ahus symptoms. 18 IMPORTANT SAFETY INFORMATION IF YOU STOP TREATMENT If you have ahus, your doctor will need to monitor you closely during and for at least 12 weeks after stopping treatment for signs of worsening ahus symptoms or problems related to abnormal clotting (thrombotic microangiopathy). Symptoms or problems that can happen with abnormal clotting may include: stroke, confusion, seizure, chest pain (angina), difficulty breathing, kidney problems, swellings in arms or legs, a drop in your platelet count. If you experience any of these problems or symptoms, it s important that you seek immediate medical care. Remember to keep your Patient Safety Card with you at all times. Please see the accompanying full Prescribing Information and Medication Guide for SOLIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections. Please see Indication and Important Safety Information on pages
14 What is the Soliris REMS program? Soliris (eculizumab) is only available through a program called the Soliris Risk Evaluation and Mitigation Strategy (REMS). Before you can receive Soliris, your doctor must: Enroll in the Soliris REMS program Counsel you about the risk of meningococcal infection Give you information about the symptoms of meningococcal infection Give you a Patient Safety Card about your risk of meningococcal infection Make sure that you are vaccinated with a meningococcal vaccine My husband was diagnosed with ahus 6 weeks ago and was vaccinated and started on Soliris therapy. He stopped plasmapheresis when he started Soliris and his doctor said that his kidney function has continued to improve. Spouse of a patient taking Soliris 14
15 Patient Safety Card 18 Below you will find a Patient Safety Card that contains information about the risk of meningococcal infection. Carry it with you at all times during your treatment and for 3 months after your last Soliris dose. Your risk of meningococcal infection may continue for several weeks after your previous dose of Soliris. It is important to show this card to any doctor or nurse who treats you in order to alert them to your risk of infection. This will help them diagnose and treat a potential meningococcal infection quickly. If you need additional copies of the Patient Safety Card, your doctor or OneSource Case Manager can provide those to you. The Patient Safety Card on this page contains important Safety Information you should know while receiving Soliris therapy. Because Soliris may reduce your natural resistance to infections, it is important to recognize the signs and symptoms of infections, including those of meningitis. This card includes a list of the signs and symptoms of these infections, so you can recognize an infection, including meningitis, and seek IMMEDIATE medical attention. Remember to keep your Patient Safety Card with you during treatment and for 3 months after your last Soliris dose. Patient Safety Card will be affixed here. Please see the accompanying full full Prescribing Information and Medication Guide for for SOLIRIS, Soliris, including Boxed Boxed WARNING Warning regarding serious and meningococcal life-threatening infection. meningococcal Please infections. see Important Please Safety see Indication Information and on Important pages Safety Information on pages
16 Indication and Important safety information for Soliris Indication and Important Safety Information for Soliris (eculizumab) INDICATION What is SOLIRIS? SOLIRIS is a prescription medicine called a monoclonal antibody. SOLIRIS is used to treat: adults and children with a disease called atypical Hemolytic Uremic Syndrome (ahus) SOLIRIS is not for use in treating people with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS) IMPORTANT SAFETY INFORMATION What is the most important information I should know about SOLIRIS? SOLIRIS is a medicine that affects your immune system. SOLIRIS can lower the ability of your immune system to fight infections. SOLIRIS increases your chance of getting serious and life-threatening meningococcal infections. Meningococcal infections may quickly become life-threatening and cause death if not recognized and treated early. 1. You must receive meningococcal vaccines at least 2 weeks before your first dose of SOLIRIS if you have not already had this vaccine. 2. If your doctor decided that urgent treatment with SOLIRIS is needed, you should receive meningococcal vaccination as soon as possible. 3. If you have not been vaccinated and SOLIRIS therapy must be initiated immediately, you should also receive 2 weeks of antibiotics with your vaccinations. 4. If you had a meningococcal vaccine in the past, you might need additional vaccination before starting SOLIRIS. Your doctor will decide if you need additional meningococcal vaccination. 5. Meningococcal vaccines reduce the risk of meningococcal infection but do not prevent all meningococcal infections. Call your doctor or get emergency medical care right away if you get any of these signs and symptoms of a meningococcal infection: headache with nausea or vomiting, headache and fever, headache with a stiff neck or stiff back, fever, fever and a rash, confusion, muscle aches with flu-like symptoms, eyes sensitive to light. 16 Please see the accompanying full Prescribing Information and Medication Guide for SOLIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections. Please see Indication and Important Safety Information on pages
17 Please see accompanying full Prescribing Information and Medication Guide for Soliris, including Boxed Warning regarding serious meningococcal infection. Please see Important Safety Information on pages
18 Indication and Important Safety Information for Soliris (eculizumab) (CONTINUED) Your doctor will give you a Patient Safety Card about the risk of meningococcal infection. Carry it with you at all times during treatment and for 3 months after your last SOLIRIS dose. Your risk of meningococcal infection may continue for several weeks after your last dose of SOLIRIS. It is important to show this card to any doctor or nurse who treats you. This will help them diagnose and treat you quickly. SOLIRIS is only available through a program called the SOLIRIS REMS. Before you can receive SOLIRIS, your doctor must: Enroll in the SOLIRIS REMS program Counsel you about the risk of meningococcal infection Give you information about the symptoms of meningococcal infection Give you a Patient Safety Card about your risk of meningococcal infection, as discussed above Make sure that you are vaccinated with a meningococcal vaccine SOLIRIS may also increase the risk of other types of serious infections. If your child is treated with SOLIRIS, make sure that your child receives vaccinations against Streptococcus pneumoniae and Haemophilus influenzae type b (Hib). Certain people may be at risk of serious infections with gonorrhea. Talk to your doctor about whether you are at risk for gonorrhea infection, about gonorrhea prevention, and regular testing. Certain fungal infections (aspergillus) may also happen if you take SOLIRIS and have a weak immune system or a low white blood cell count. Who should not receive SOLIRIS? Do not receive SOLIRIS if you: have a meningococcal infection. have not been vaccinated against meningitis infection unless your doctor decides that urgent treatment with SOLIRIS is needed. See What is the most important information I should know about SOLIRIS? 18 Please see the accompanying full Prescribing Information and Medication Guide for SOLIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections. Please see Indication and Important Safety Information on pages
19 Before you receive SOLIRIS, tell your doctor about all of your medical conditions, including if you: have an infection or fever. are pregnant or plan to become pregnant. It is not known if SOLIRIS will harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if SOLIRIS passes into your breast milk. Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. SOLIRIS (eculizumab) and other medicines can affect each other causing side effects. It is important that you: have all recommended vaccinations before you start SOLIRIS receive 2 weeks of antibiotics if you immediately start SOLIRIS stay up-to-date with all recommended vaccinations during treatment with SOLIRIS Know the medications you take and the vaccines you receive. Keep a list of them to show your doctor and pharmacist when you get a new medicine. Monitoring Disease After Stopping SOLIRIS If you have ahus, your doctor will need to monitor you closely during treatment and for at least 12 weeks after stopping treatment for signs of worsening ahus symptoms or problems related to abnormal clotting (thrombotic microangiopathy). Symptoms or problems that can happen with abnormal clotting may include: stroke, confusion, seizure, chest pain (angina), difficulty breathing, kidney problems, swellings in arms or legs, a drop in your platelet count. 19
20 Indication and Important Safety Information for Soliris (eculizumab) (CONTINUED) WHAT ARE THE POSSIBLE SIDE EFFECTS OF SOLIRIS? SOLIRIS can cause serious side effects including: See What is the most important information I should know about SOLIRIS? Serious allergic reactions. Serious allergic reactions can happen during your SOLIRIS infusion. Tell your doctor or nurse right away if you notice any of these symptoms during your SOLIRIS infusion: chest pain; trouble breathing or shortness of breath; swelling of your face, tongue, or throat; feel faint or pass out If you have an allergic reaction to SOLIRIS, your doctor may need to infuse SOLIRIS more slowly, or stop SOLIRIS. See How will I receive SOLIRIS? in the Medication Guide. The most common side effects in people with ahus treated with SOLIRIS include: headache, diarrhea, high blood pressure (hypertension), common cold (upper respiratory infection), stomach-area (abdominal pain), vomiting, pain or swelling of your nose or throat (nasopharyngitis), low red blood cell count (anemia), cough, swelling of legs or feet (peripheral edema), nausea, urinary tract infections, fever. Tell your doctor about any side effect that bothers you or that does not go away. These are not all the possible side effects of SOLIRIS. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at FDA Please see the accompanying full Prescribing Information and Medication Guide for SOLIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections. 20 Please see Indication and Important Safety Information on pages
21 21
22 Where can I find out more? Additional resources are available to help answer your questions about ahus and Soliris (eculizumab). The complimentary OneSource program is staffed by Case Managers to offer support to both you and your doctor. Case Managers have clinical knowledge and funding expertise OneSource can help you transition from hospital to home OneSource Case Managers are assigned geographically, so they re familiar with doctors, hospitals, community resources, and funding opportunities close to home Visit or call SOLIRIS ( ) to speak one-on-one with a OneSource Case Manager today! You are encouraged to report serious side effects of prescription drugs to the FDA. Visit or call FDA.1088 ( ). 22 Please see the accompanying full Prescribing Information and Medication Guide for SOLIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections. Please see Indication and Important Safety Information on pages
23 If your doctor determines that Soliris (eculizumab) is the right treatment for you, you may learn more by visiting the Soliris website or speaking with a OneSource Case Manager. Case Managers can be an important source of information and support as you navigate this complicated disease. They are trained to: Work with your healthcare team to answer questions and provide educational materials related to ahus Assist you with insurance coverage and funding options Help with solutions for balancing all aspects of ahus management when faced with major life challenges, such as helping you schedule infusions and finding alternative infusion centers if you are traveling 23
24 Glossary Allergic reaction: an overreaction of the immune system after a substance is introduced into the body. Atypical hemolytic uremic syndrome (ahus): a disease of the blood that causes low red blood cell and platelet counts, kidney failure, and sometimes damage to other vital organs, such as the heart and brain. Blood clot: blood that has changed from liquid to a gel-like or semisolid clump. Blood vessels: tubular structures that carry blood through the human body. Cells: the smallest structural and functional units of the human body. Complement system: a natural part of the immune system that helps protect the body from foreign substances like bacteria or other infections. The complement system is made up of a group of proteins found in the blood. Dialysis: a treatment for kidney failure. Normally, the kidneys work to filter the blood and remove waste, excess salt, and water. Kidney failure, also called end-stage renal disease, occurs when the kidneys stop working completely. During hemodialysis, a machine takes over the job of the kidneys by filtering the blood outside of the body and then returning the filtered blood back to the body. FDA: Food and Drug Administration, the US federal agency that assures the safety and efficacy of drugs, foods, and other products. Genetic: relating to genes, which are units in cells that are passed down through families. Immune system: a complex group of cells, proteins, and other molecules that work together to identify foreign organisms and other substances, such as bacteria; the main role of the system is to protect the body against these foreign organisms. Infusion: a process during which fluid is introduced into the body through a vein. Meningococcal infections: infections caused by a group of bacteria called Neisseria meningitidis. The most common forms of meningococcal infections include meningitis (infection of the membranes that surround the brain and spinal cord) and meningococcemia (bloodstream infections). Platelets: small, irregular, disc-shaped elements in the blood that assist in blood clotting. REMS (Risk Evaluation and Mitigation Strategy): a program required by the FDA to manage known or potential serious risks associated with a drug product. Thrombotic microangiopathy (TMA): formation of clots in small blood vessels throughout the body; this is an underlying cause of the clinical signs and symptoms of ahus. Vaccine: a preparation that is used to increase the body s natural defense against a disease. 24
25 References 1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17): Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial ahus and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10): Holers VM. The spectrum of complement alternative pathway-mediated diseases. Immunol Rev. 2008;223(1): Zipfel PF, Heinen S, Skerka C. Thrombotic microangiopathies: new insights and new challenges. Curr Opin Nephrol Hypertens. 2010;19(4): Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol. 2012;8(11): Liszewski MK, Atkinson JP. Too much of a good thing at the site of tissue injury: the instructive example of the complement system predisposing to thrombotic microangiopathy. Hematol Am Soc Hematol Educ Program. 2011;2011(1): Fang CJ, Richards A, Liszewski MK, Kavanagh D, Atkinson JP. Advances in understanding of pathogenesis of ahus and HELLP. Br J Haematol. 2008;14(3): Campistol JM, Arias M, Ariceta G, et al. An update for atypical hemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia. 2015;35(5): Fakhouri F, Roumenina L, Provot F, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol. 2010;21(5): Geerdink LM, Westra D, van Wijk JAE, et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol. 2012;27(8): Langman C. Systemic multi-organ complications in atypical hemolytic uremic syndrome (ahus): retrospective study in a medical practice setting. Haematologica. 2012:97(s1): Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 2001;60(3): Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fremeaux-Bacchi V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8: Fakhouri F, Hourmant M, Campistol JM, et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kid Dis. 2016;68(1): Greenbaum LA, Fila M, Ardissino G, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89(3): Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23): Licht C, Greenbaum LA, Muus P, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-Year extensions of phase 2 studies. Kidney Int. 2015;87(5): Soliris [prescribing information]. Boston, MA: Alexion Pharmaceuticals; Bouts A, Monnens L, Davin JC, Struijk G, Spanjaard L. Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy. Pediatr Nephrol. 2011;26: Please see the accompanying full Prescribing Information and Medication Guide for SOLIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections. Please see Indication and Important Safety Information on pages
26 Notes 26
PATIENT SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR PATIENTS. Before starting on Soliris Important safety information for patients
PATIENT SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR PATIENTS Before starting on Soliris Important safety information for patients Before you begin Soliris (eculizumab) treatment, your physician will
More informationBefore starting on Soliris.
Before starting on Soliris. Important safety information for patients Before you begin Soliris (eculizumab) treatment, your physician will give you a: Medication Guide Soliris Patient Safety Information
More informationPRESCRIBER SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR THE HEALTHCARE PROVIDER
PRESCRIBER SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR THE HEALTHCARE PROVIDER BEFORE STARTING YOUR PATIENTS ON SOLIRIS Important safety information for the healthcare provider Prior to initiating
More informationHow are unresolved Myasthenia Gravis symptoms disrupting your day? Talk to your doctor about your symptoms
How are unresolved Myasthenia Gravis symptoms disrupting your day? Talk to your doctor about your symptoms Recognize the symptoms of your generalized Myasthenia Gravis (gmg) Anti-acetylcholine receptor
More informationIF YOU HAVE PNH, YOU ARE NOT ALONE. Take a closer look and take control of PNH US/SOL-P/0005
IF YOU HAVE PNH, YOU ARE NOT ALONE Take a closer look and take control of PNH INDICATION & IMPORTANT SAFETY INFORMATION FOR SOLIRIS (eculizumab) INDICATION What is SOLIRIS? SOLIRIS is a prescription medicine
More informationIF YOU HAVE PNH, YOU ARE NOT ALONE. Take a closer look and take control of PNH
IF YOU HAVE PNH, YOU ARE NOT ALONE Take a closer look and take control of PNH Indication and Usage Paroxysmal Nocturnal Hemoglobinuria (PNH) Soliris (eculizumab) is indicated for the treatment of patients
More informationWARNING: SERIOUS MENINGOCOCCAL INFECTIONS
Indication and Usage Paroxysmal Nocturnal Hemoglobinuria (PNH) Soliris (eculizumab) is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. WARNING:
More informationA PATIENT S JOURNEY. Learning about atypical hemolytic uremic syndrome (ahus)
A PATIENT S JOURNEY Learning about atypical hemolytic uremic syndrome (ahus) Begin your path to empowerment Being diagnosed with ahus can be overwhelming. You may have many questions: What is ahus? How
More informationSoliris (eculizumab) For the Treatment of PNH to Reduce Hemolysis
Soliris (eculizumab) You have done well to manage your PNH with Soliris. Living with a rare disease, like PNH, can be challenging, but by sticking with your Soliris therapy, you are doing a lot to help
More informationA CAREGIVER S JOURNEY
A CAREGIVER S JOURNEY Learning about atypical hemolytic uremic syndrome (ahus) Begin your path to effective advocacy and support Caring for someone who is diagnosed with ahus can be overwhelming. You may
More informationULTOMIRIS is the fi rst and only long-acting medication approved by the FDA dosed every 8 weeks a to treat PNH in adults
Introducing ULTOMIRIS (ravulizumab-cwvz) for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) FOR NEW PATIENTS ULTOMIRIS is the fi rst and only long-acting medication approved
More informationPNH ahus. Dosing and Administration. For Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (ahus) patients
For Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (ahus) patients PNH ahus Dosing and Administration Soliris is indicated for the treatment of patients with paroxysmal
More informationPNH ahus gmg. Dosing and Administration Guide
Injection for Intravenous Use PNH ahus gmg For Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (ahus), and generalized Myasthenia Gravis (gmg) patients Dosing and Administration
More informationahus A PATIENT S GUIDE To learn more about ahus, visit Copyright 2011, Alexion Pharmaceuticals, Inc. All rights reserved.
To learn more about ahus, visit www.ahussource.com ahus A PATIENT S GUIDE Copyright 2011, Alexion Pharmaceuticals, Inc. All rights reserved. SOL 1169 BECOME EMPOWERED By learning more and taking control
More informationULTOMIRIS is the fi rst and only long-acting medication approved by the FDA dosed every 8 weeks a to treat PNH in adults
Introducing ULTOMIRIS (ravulizumab-cwvz) for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) FOR PATIENTS ULTOMIRIS is the fi rst and only long-acting medication approved
More informationMEDICATION GUIDE. BENLYSTA (ben-list-ah) (belimumab) Injection for intravenous use
MEDICATION GUIDE BENLYSTA (ben-list-ah) (belimumab) Injection for intravenous use Read this Medication Guide before you start receiving BENLYSTA and before each treatment. There may be new information.
More informationHave a healthy discussion. Use this guide to start a. conversation. with your. healthcare provider
Have a healthy discussion Use this guide to start a conversation with your healthcare provider MAKE THE CONVERSATION COUNT Here are some things you may want to reflect on and discuss with your healthcare
More informationSoliris (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome (ahus)
Soliris (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome (ahus) New Data from the Largest Prospective Trial of Adult Patients
More informationA treatment to fit your needs
A treatment to fit your needs Aranesp (darbepoetin alfa) is a prescription medicine used to treat a lower than normal number of red blood cells (anemia) caused by chronic kidney disease in patients on
More informationSoliris (eculizumab): Paroxysmal nocturnal haemoglobinuria (PNH) Patient/Parent information brochure
Soliris (eculizumab): Paroxysmal nocturnal haemoglobinuria (PNH) Patient/Parent information brochure CONTENTS PAGE GLOSSARY TERMS INTRODUCTION WHAT IS SOLIRIS? FREQUENTLY ASKED QUESTIONS WHAT ARE THE SAFETY
More informationGetting started with PROMACTA (eltrombopag)
Getting started with PROMACTA (eltrombopag) Indications PROMACTA is a prescription medicine used to treat adults and children 1 year and older with low blood platelet counts due to chronic immune (idiopathic)
More informationREADY. SET. DOPTELET. HELP GET READY FOR YOUR UPCOMING PROCEDURE
HELP GET READY FOR YOUR UPCOMING PROCEDURE READY. SET. DOPTELET. Full Prescribing Information for DOPTELET (avatrombopag), including Patient For adults with chronic liver disease and a low platelet count
More informationSoliris. Soliris (eculizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.11 Subject: Soliris Page: 1 of 5 Last Review Date: September 20, 2018 Soliris Description Soliris
More informationHow does my new treatment work?
How does my new treatment work? Get to know KEVZARA better. Click here for full Prescribing Information including 1 risk of SERIOUS SIDE EFFECTS and Medication Guide. You're starting KEVZARA... GOT A QUESTION?
More informationSafety and Efficacy of Eculizumab in Pediatric Patients With ahus, With or Without Baseline Dialysis
SA-PO546 Safety and Efficacy of Eculizumab in Pediatric Patients With ahus, With or Without Baseline Johan Vande Walle, 1 Larry A. Greenbaum, 2 Camille L. Bedrosian, 3 Masayo Ogawa, 3 John F. Kincaid,
More informationFuel your determination to live longer with KYPROLIS. Look inside to learn more.
F O R R E L A P S E D MULT IP L E M Y E L OM A APPROVED USES KYPROLIS is a prescription medication used to treat patients with relapsed or refractory multiple myeloma who have received one to three previous
More informationSoliris Medical Policy Prior Authorization Program Summary
Soliris Medical Policy Prior Authorization Program Summary Precertification/Prior Authorization may be required under certain plans. Please verify each member s benefits. OBJECTIVE The intent of the Soliris
More informationI. ALL CLAIMS: HEALTH CARE PROFESSIONALS
HCP Prescribing Information Date/Version January 2015 Version 2 Page: 1 of 5 I. ALL CLAIMS: HEALTH CARE PROFESSIONALS Indications and Usage Saxenda (liraglutide [rdna origin] injection) is indicated as
More informationUnderstanding your risk of blood clots from hospital to home and how Bevyxxa may help
Understanding your risk of blood clots from hospital to home and how Bevyxxa may help People who take Bevyxxa and have medicine injected into their spinal and epidural area, or have a spinal puncture,
More informationQuestions to ask your Doctor
Questions to ask your Doctor What is my current blood pressure? What are my target blood pressure numbers? What blood pressure medication(s) am I currently taking? How is this drug different from what
More informationOne daily pill can help prevent HIV. TRUVADA for PrEP, together with safer sex practices, can mean better protection.
TRUVADA for PrEP is a prescription medicine that can help reduce the risk of getting HIV-1 through sex, when taken every day and used together with safer sex practices. TRUVADA for PrEP is only for people
More informationA GUIDE TO STARTING TREATMENT
A GUIDE TO STARTING TREATMENT Please see accompanying and Medication Guide. full Prescribing IDHIFA (enasidenib) is a prescription medicine used to treat people with acute myeloid leukemia (AML) with an
More informationMEDICATION GUIDE. Epogen (Ee-po-jen) (epoetin alfa)
MEDICATION GUIDE Epogen (Ee-po-jen) (epoetin alfa) Read this Medication Guide before you start Epogen, each time you refill your prescription, and if you are told by your healthcare provider that there
More informationRandy J. EMPLICITI patient Ready to get started
Randy J. EMPLICITI patient Ready to get started PICTURE YOUR IMMUNE SYSTEM AT WORK AGAINST MULTIPLE MYELOMA Randy J. EMPLICITI patient My body taking on multiple myeloma What is EMPLICITI? EMPLICITI is
More informationThe ORENCIA (abatacept) JIA Observational Registry
Moderate to Severe Juvenile Idiopathic Arthritis (JIA) Injection for Intravenous Use Injection for Subcutaneous Use The ORENCIA (abatacept) JIA Observational Registry Injection for Intravenous Use Injection
More informationoffers the possibility of a longer life 1 BLINCYTO A guide for patients and caregivers
In a study of 405 adults with Philadelphia chromosome negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia, 271 were treated with BLINCYTO and 134 with chemotherapy. The adults
More informationBLINCYTO can eliminate detectable traces of cancer 1
For people* with B-cell precursor ALL who are MRD+, 1 BLINCYTO can eliminate detectable traces of cancer 1 In a study of 86 adults with MRD+ B-cell precursor ALL, BLINCYTO removed detectable traces of
More informationUstekinumab (Stelara ) Therapy for Crohn s Disease
Patient & Family Guide 2017 Ustekinumab (Stelara ) Therapy for Crohn s Disease www.nshealth.ca Ustekinumab (Stelara ) Therapy Your healthcare provider believes treatment with a medicine called ustekinumab
More informationYour guide to taking LENVIMA for hepatocellular carcinoma (HCC), a type of liver cancer
Your guide to taking LENVIMA for hepatocellular carcinoma (HCC), a type of liver cancer LENVIMA is a prescription medicine that is used by itself as the first treatment for a type of liver cancer called
More informationWhat You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide
For Patients What You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide Patients: Your doctor or nurse will go over this patient guide with you. It is important to ask any questions
More informationStarting KAZANO gave me MORE POWER than metformin alone, with 2 medicines in 1 tablet
For many adults with type 2 diabetes Starting KAZANO gave me MORE POWER than metformin alone, with 2 medicines in 1 tablet Individual results may vary. Not actual patient. KAZANO is a prescription medicine
More informationSafety and Efficacy of Eculizumab in Pediatric Patients With ahus, With or Without Baseline Dialysis
SP281 Safety and Efficacy of Eculizumab in Pediatric Patients With ahus, With or Without Baseline Johan Vande Walle, 1 Larry A. Greenbaum, 2 Camille L. Bedrosian, 3 Masayo Ogawa, 3 John F. Kincaid, 3 Chantal
More informationDoes yours? Most school-age kids with asthma have allergic asthma. Enroll in our support program. Learn about this distinct condition
Most school-age kids with asthma have allergic asthma. Does yours? Learn about this distinct condition Enroll in our support program for tools, information on financial resources, and more at GetSupportForYou.com
More informationWhat are my treatment support resources?
What are my treatment support resources? Get help when you need it. Click here for full Prescribing Information including risk of SERIOUS SIDE EFFECTS and Medication Guide. We re here to help you......
More informationWhat You Need to Know About ARZERRA (ofatumumab)
Starting your treatment for chronic lymphocytic leukemia (CLL) What You Need to Know About ARZERRA (ofatumumab) Approved Use ARZERRA is a prescription medication used: With a chemotherapy drug called chlorambucil
More informationRick N. EMPLICITI patient Ready to get started
Rick N. EMPLICITI patient Ready to get started PICTURE YOUR IMMUNE SYSTEM AT WORK AGAINST MULTIPLE MYELOMA Rick N. EMPLICITI patient My body taking on multiple myeloma What is EMPLICITI? EMPLICITI is a
More informationDexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop.
Dexamethasone Other Names: Decadron About This Drug Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop. Possible Side Effects (More Common) Increased
More informationMedication Guide Plavix (PLAV-iks) (clopidogrel bisulfate) tablets
Medication Guide Plavix (PLAV-iks) (clopidogrel bisulfate) tablets Read this Medication Guide before you start taking Plavix and each time you get a refill. There may be new information. This Medication
More informationwas proven to help people live longer1 BLINCYTO A guide for patients and caregivers
In a clinical trial for people with a certain kind of ALL whose cancer has returned or didn t respond to treatment 1 BLINCYTO was proven to help people live longer1 In a study of 405 adults with ALL, 271
More informationMedication Tracker for ZYTIGA (abiraterone acetate)
Medication Tracker for YTIGA (abiraterone acetate) See the next page to help set up a medication schedule that works for you, as directed by your doctor. Write in the administration times that suit you
More informationWhat is the most important information I should know about bortezomib? What should I discuss with my healthcare provider before receiving bortezomib?
1 of 5 6/10/2016 3:46 PM Generic Name: bortezomib (bor TEZ oh mib) Brand Name: Velcade What is bortezomib? Bortezomib interferes with the growth of some cancer cells and keeps them from spreading in your
More informationInlyta (axitinib) for Kidney Cancer
Inlyta (axitinib) for Kidney Cancer Inlyta is a medication used to treat advanced kidney cancer in adults when one prior drug treatment for this disease has not worked Dosage: 5mg taken twice a day How
More informationPeople who have received 1-3 prior treatments for their multiple myeloma may receive: Revlimid (lenalidomide)
FINDTHE THE FIND STRENGTH STRENGTH WITHIN WITHIN TOHELP HELPFIGHT FIGHT TO MULTIPLEMYELOMA MYELOMA MULTIPLE Rick N. N. patient Rick patient What is? is a prescription medicine used with other medications
More informationYOUR CABOMETYX HANDBOOK
YOUR CABOMETYX HANDBOOK AN OVERVIEW FOR PATIENTS AND CAREGIVERS in the full Prescribing Information. Table of Contents What s included in this handbook... 3 A kidney cancer overview...4 About CABOMETYX...4
More informationLIVE LONGER. Chart a course that could help you. If multiple myeloma comes back:
1 If multiple myeloma comes back: Chart a course that could help you 1 LIVE LONGER -3 In two clinical studies with patients with relapsed multiple myeloma, two KYPROLIS -based combinations kept multiple
More informationDEDICATED SUPPORT TO HELP YOU GET STARTED AND STAY ON TRACK THROUGHOUT YOUR TREATMENT
LET US HELP YOU FIND A CLEARER PATH FORWARD. DEDICATED SUPPORT TO HELP YOU GET STARTED AND STAY ON TRACK THROUGHOUT YOUR TREATMENT PERSONALIZED SUPPORT FREE MEDICATION* $0 CO-PAY* WELCOME KIT RECYCLABLE
More informationMEDICATION GUIDE. The risk of getting a serious skin rash is higher if you:
MEDICATION GUIDE Lamotrigine (lam-oh-try-jeen) Tablets USP Rx only What is the most important information I should know about lamotrigine tablets? 1. Lamotrigine tablets may cause a serious skin rash that
More informationGet an Insurance Benefits Review for ORENCIA (abatacept)
Get an Insurance Benefits Review for ORENCIA (abatacept) If you and your doctor decide that ORENCIA is right for you, you can call 1-800-ORENCIA (1-800-673-6242) to do an Insurance Benefits Review. Our
More informationFor males: use effective birth control during your treatment with INLYTA. Talk to your doctor about birth control methods.
PATIENT INFORMATION INLYTA (in-ly-ta) (axitinib) tablets Read this Patient Information before you start taking INLYTA and each time you get a refill. There may be new information. This information does
More informationFOR PATIENTS WITH SYMPTOMS OF SARCOIDOSIS. Treatment Journal. H.P. Acthar Gel is a prescription medication used to treat symptoms of sarcoidosis.
FOR PATIENTS WITH SYMPTOMS OF SARCOIDOSIS Treatment Journal H.P. Acthar Gel is a prescription medication used to treat symptoms of sarcoidosis. IMPORTANT SAFETY INFORMATION Who should NOT take Acthar?
More informationTake on IPF progression with OFEV
Every breath matters Take on IPF progression with OFEV Learn more at www.ofev.com IPF=idiopathic pulmonary fibrosis. Please see throughout Understand how IPF affects you Idiopathic pulmonary fibrosis (IPF)
More informationKeeping track of your numbers
Keeping track of your numbers If you have relapsed or refractory multiple myeloma, keeping track of your numbers can help you take an active role in your care. It s also one way you and your doctor can
More informationGAZYVA for Chronic Lymphocytic Leukemia (CLL)
GAZYVA for Chronic Lymphocytic Leukemia (CLL) GAZYVA is a prescription medicine used with the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in adults who have not had previous
More informationTuscarawas County Health Department. Vivitrol Treatment Consent
Tuscarawas County Health Department Vivitrol Treatment Consent I. Vivitrol Medication Guide: a. VIVITROL (viv-i-trol) (naltrexone for extended-release injectable suspension) b. Read this Medication Guide
More informationTips to Help Treat Diarrhea, Nausea, and Vomiting Side Effects
Tips to Help Treat Diarrhea, Nausea, and Vomiting Side Effects If you have been prescribed OFEV (nintedanib) capsules for the treatment of idiopathic pulmonary fibrosis (IPF) this brochure can help you
More informationTalking about your treatment. A guide to the conversations you may have before starting LEMTRADA
Talking about your treatment A guide to the conversations you may have before starting LEMTRADA INTRODUCTION HEALTHCARE TEAM CARE TEAM COWORKERS Please see Important Safety Information on pages 6-7 and
More informationIf you wake up to urinate 2 or more times a night, ask your doctor about NOCTIVA
If you wake up to urinate 2 or more times a night, ask your doctor about NOCTIVA IMPORTANT SAFETY INFORMATION WARNING: HYPONATREMIA See full prescribing information for complete boxed warning. NOCTIVA
More informationPatient Information VERSACLOZ (VER sa kloz) (clozapine) Oral Suspension
Patient Information VERSACLOZ (VER sa kloz) (clozapine) Oral Suspension Read this Patient Information before you start taking VERSACLOZ and each time you get a refill. There may be new information. This
More informationDiscussion guide. Questions to bring to your next doctor s appointment. Notes
Discussion guide Questions to bring to your next doctor s appointment As someone who has had a heart attack or has peripheral arterial disease (PAD), it s important to lower your chance of having a heart
More informationM.Weitz has documented that he has no relevant financial relationships to disclose or conflict of interest to resolve.
M.Weitz has documented that he has no relevant financial relationships to disclose or conflict of interest to resolve. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic
More informationSoliris (eculizumab): Physician s guide to prescribing for patients with refractory generalised myasthenia gravis (gmg)
Soliris (eculizumab): Physician s guide to prescribing for patients with refractory generalised myasthenia gravis (gmg) CONTENTS PAGE WHAT IS SOLIRIS? SOLIRIS INDICATIONS IMPORTANT SAFETY INFORMATION SOLIRIS
More informationMEDICATION GUIDE Abacavir, Lamivudine and Zidovudine Tablets (a-bak-a-vir, la-miv-ue-deen, zye-doe-vue-deen)
MEDICATION GUIDE Abacavir, Lamivudine and Zidovudine Tablets (a-bak-a-vir, la-miv-ue-deen, zye-doe-vue-deen) What is the most important information I should know about abacavir, lamivudine and zidovudine
More informationImportant Safety Information About TRUVADA to Reduce the Risk of Getting Human Immunodeficiency Virus 1 (HIV-1) Infection
Important Safety Information About TRUVADA to Reduce the Risk of Getting Human Immunodeficiency Virus 1 (HIV-1) Infection This booklet is for adults taking TRUVADA to reduce the risk of getting HIV-1 infection.
More informationThank you for downloading this patient assistance document from NeedyMeds. We hope this program will help you get the medicine you need.
Thank you for downloading this patient assistance document from NeedyMeds. We hope this program will help you get the medicine you need. Did you know that NeedyMeds has thousands of other free resources?
More informationPatient Information IXEMPRA Kit (pronounced as ǐk-'sĕm-pră) (ixabepilone) What is the most important information I should know about IXEMPRA?
17.6 FDA-Approved Patient Labeling Patient Information IXEMPRA Kit (pronounced as ǐk-'sĕm-pră) (ixabepilone) for Injection, for intravenous infusion only Read the Patient Information that comes with IXEMPRA
More informationOseltamivir phosphate capsule does not treat or prevent illness that is caused by infections other than the influenza virus.
PATIENT INFORMATION Oseltamivir Phosphate Capsules USP, for oral use (OH-sel-TAM-i-vir FOS-fate) What is oseltamivir phosphate capsule? Oseltamivir phosphate capsule is a prescription medicine used to:
More informationORENCIA (oh-ren-see-ah) (abatacept)
17.7 FDA-Approved Patient Labeling PATIENT INFORMATION ORENCIA (oh-ren-see-ah) (abatacept) Read this Patient Information before you start receiving ORENCIA and each time before you are scheduled to receive
More informationMEDICATION GUIDE XIGDUO XR (ZIG- DO- OH X- R) (dapagliflozin and metformin HCL extended-release) Tablets
XIGDUO XR (dapagliflozin and metformin HCl extended-release) tablets 5 MEDICATION GUIDE XIGDUO XR (ZIG- DO- OH X- R) (dapagliflozin and metformin HCL extended-release) Tablets What is the most important
More informationMethotrexate. About This Drug. Possible Side Effects. Warnings and Precautions
Methotrexate About This Drug Methotrexate is used to treat cancer. This drug is given in the vein (IV). Possible Side Effects Soreness of the mouth and throat. You may have red areas, white patches, or
More informationHELPING LIFT YOU THROUGH YOUR JOURNEY WITH SYMPTOMATIC SARCOIDOSIS
HELPING LIFT YOU THROUGH YOUR JOURNEY WITH SYMPTOMATIC SARCOIDOSIS Your Guide to Acthar SUPPORTING YOU FROM THE START OF YOUR TREATMENT H.P. Acthar Gel is a prescription medicine for people with symptoms
More informationOF HIS TREATMENT FOR RELAPSED MULTIPLE MYELOMA. Understanding the steps on your treatment journey
EMMETT TAKES CHARGE OF HIS TREATMENT FOR RELAPSED MULTIPLE MYELOMA Understanding the steps on your treatment journey APPROVED USE KYPROLIS (carfilzomib) is a prescription medication used to treat patients
More informationTake the next step with Strensiq.
Introducing Strensiq : the first and only treatment for people with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP) Take the next step with Strensiq. Strensiq can improve bone health in
More informationBCHOOSE TO VACCINATED. Ask your doctor about the MenB * vaccine.
BCHOOSE TO VACCINATED Vaccinate against meningococcal disease caused by Neisseria meningitidis group B strains (MenB) with BEXSERO BEXSERO multicomponent meningococcal B vaccine (recombinant, adsorbed)
More informationyour breathing problems worsen quickly. you use your rescue inhaler, but it does not relieve your breathing problems.
MEDICATION GUIDE ADVAIR DISKUS [ad vair disk us] (fluticasone propionate and salmeterol inhalation powder) for oral inhalation What is the most important information I should know about ADVAIR DISKUS?
More informationDiscover CRYSVITA and Redefine XLH TREATMENT
Discover CRYSVITA and Redefine XLH TREATMENT CRYSVITA is a prescription medicine used to treat adults and children 1 year of age and older with X-linked hypophosphatemia (XLH). 10 mg/ml, 20 mg/ml, 30 mg/ml
More informationMEDICATION GUIDE. (tocilizumab)
MEDICATION GUIDE ACTEMRA (AC-TEM-RA) (tocilizumab) Read this Medication Guide before you start ACTEMRA and before each infusion. There may be new information. This Medication Guide does not take the place
More informationPatient Information Losartan Potassium and Hydrochlorothiazide Tablets, USP 50 mg/12.5 mg, 100 mg/12.5 mg and 100 mg/25 mg Rx only
Patient Information Losartan Potassium and Hydrochlorothiazide Tablets, USP 50 mg/12.5 mg, 100 mg/12.5 mg and 100 mg/25 mg Rx only Read the Patient Information that comes with Losartan Potassium and Hydrochlorothiazide
More informationWhen a patient presents with TMA, identify the underlying cause for the appropriate diagnosis... IS IT TTP OR IS IT ahus?
When a patient presents with TMA, identify the underlying cause for the appropriate diagnosis... IS IT TTP OR IS IT ahus? ADAMTS13 activity >5% RULES OUT a diagnosis of severe ADAMTS13 deficiency (TTP)
More informationDiscussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor
Discussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor TECENTRIQ DISCUSSION SUPPORT What is TECENTRIQ? TECENTRIQ is a prescription medicine used to treat: A type of bladder
More informationActhar TREATMENT JOURNAL
Acthar TREATMENT JOURNAL Help for patients in the grip of dermatomyositis or polymyositis What is Acthar? Acthar is a prescription medicine used for flares or on a regular basis (maintenance) in people
More informationWhat should I ask my treatment team?
TREATMENT TRANSFORMED Child portrayed is not a real KYMRIAH patient. DISCUSSION GUIDE What should I ask my treatment team? Making treatment decisions for relapsed or refractory cancer can be hard. Asking
More informationMEDICATION GUIDE ELIQUIS (ELL eh kwiss) (apixaban) tablets
MEDICATION GUIDE ELIQUIS (ELL eh kwiss) (apixaban) tablets What is the most important information I should know about ELIQUIS? For people taking ELIQUIS for atrial fibrillation: People with atrial fibrillation
More informationMEDICATION GUIDE Prasugrel (pra-su-grel) tablets Read this Medication Guide before you start taking prasugrel and each time you get a refill.
MEDICATION GUIDE Prasugrel (pra-su-grel) tablets Read this Medication Guide before you start taking prasugrel and each time you get a refill. There may be new information. This Medication Guide does not
More informationMEDICATION GUIDE. (belatacept) For Injection, For Intravenous Use
MEDICATION GUIDE NULOJIX (noo-loj-jiks) (belatacept) For Injection, For Intravenous Use Read this Medication Guide before you start receiving NULOJIX and before each treatment. There may be new information.
More informationPREVENTING BROKEN BONES:
PREVENTING BROKEN BONES: Your guide to understanding how XGEVA can help prevent broken bones and other serious bone problems* when cancer from solid tumors spreads to your bones.1 *Serious bone problems
More informationH1N1 and Flu Shots During Pregnancy
H1N1 and Flu Shots During Pregnancy HEALTH EDUCATION HEALTH EDUCATION The H1N1 flu and seasonal vaccines are safe and recommended for pregnant women. Be sure to: Get the H1N1 flu vaccine for yourself and
More informationAVEED TESTOSTERONE INJECTION. Not an actual patient.
Ask your healthcare provider about LONG-ACTING AVEED AVEED TESTOSTERONE INJECTION 5 SHOTS A YEAR AFTER THE FIRST MONTH OF THERAPY Not an actual patient. AVEED is a prescription medicine that contains testosterone,
More informationONE PILL, ONCE A DAY GET TO KNOW AUBAGIO. Ask your doctor if AUBAGIO may be right for you. Patient Portrayal
ONE PILL, ONCE A DAY GET TO KNOW AUBAGIO Patient Portrayal Ask your doctor if AUBAGIO may be right for you. INDICATION AUBAGIO (teriflunomide) is a prescription medicine used to treat relapsing forms of
More informationSoliris (eculizumab) DRUG.00050
Market DC Soliris (eculizumab) DRUG.00050 Override(s) Prior Authorization Approval Duration 1 year Medications Soliris (eculizumab) APPROVAL CRITERIA Paroxysmal Nocturnal Hemoglobinuria I. Initiation of
More information(sunitinib malate) for Kidney Cancer
Sutent (sunitinib malate) for Kidney Cancer Sutent is a medication used to treat adult patients with kidney cancer that has been surgically removed and at high risk of recurrence, or advanced kidney cancer
More information